Also, based on trials that included data on CV and renal outcomes, the frequently updated international guidelines from the ADA and European Association for the Study of Diabetes (EASD) [25, 26] recommend using a more expensive antidiabetic therapy, namely GLP-1 receptor agonists and SGLT2 inhibitors, in diabetes patients with CV or renal complications or who are at higher risk for development of those diabetes-related complications, for the reduction of such events. The gene discussed is GLP1R; the disease is diabetes mellitus.